Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
, 52, 22-28

Exogenous Melatonin as a Treatment for Secondary Sleep Disorders: A Systematic Review and Meta-Analysis

Affiliations
Meta-Analysis

Exogenous Melatonin as a Treatment for Secondary Sleep Disorders: A Systematic Review and Meta-Analysis

Tian Li et al. Front Neuroendocrinol.

Abstract

Melatonin is a physiological indoleamine involved in circadian rhythm regulation and it is currently used for secondary sleep disorders supported by empirical evidence. A small amount of evidence and some controversial results have been obtained in some randomized controlled trials (RCT). The objective of this meta-analysis is to determine the efficacy of exogenous melatonin versus placebo in managing secondary sleep disorders. Literature retrieval of eligible RCT was performed in 5 databases (PubMed, Embase, Cochrane Library, ClinicalTrials.gov, and Web of Science). In total, 7 studies of 205 patients were included. Pooled data demonstrate that exogenous melatonin lowers sleep onset latency and increases total sleep time, whereas it has little if any effect on sleep efficiency. Although, the efficacy of melatonin still requires further confirmation, this meta-analysis clearly supports the use of melatonin as a management for patients with secondary sleep disorders.

Keywords: Melatonin; Meta-analysis; Secondary sleep disorders; Sleep efficiency; Sleep onset latency; Total sleep time.

Similar articles

See all similar articles

Cited by 5 PubMed Central articles

  • Sleep-Related Disorders in Neurology and Psychiatry
    J Rémi et al. Dtsch Arztebl Int 116 (41), 681-688. PMID 31709972.
    Sleep disorders in neurology and psychiatry are a heterogeneous group of disorders with diverse manifestations. Their proper diagnosis and treatment can help prevent seco …
  • Melatonin: Clinical Perspectives in Neurodegeneration
    DP Cardinali. Front Endocrinol (Lausanne) 10, 480. PMID 31379746. - Review
    Prevention of neurodegenerative diseases is presently a major goal for our Society and melatonin, an unusual phylogenetically conserved molecule present in all aerobic or …
  • Circadian Rhythms: Will It Revolutionise the Management of Diseases?
    A Seifalian et al. J Lifestyle Med 9 (1), 1-11. PMID 30918828. - Review
    The Nobel Prize for Medicine in 2017 was awarded to Michael Young, Michael Rosbash and Jeffrey Hall for their discoveries into the molecular mechanisms controlling circad …
  • AMPK: Potential Therapeutic Target for Ischemic Stroke
    S Jiang et al. Theranostics 8 (16), 4535-4551. PMID 30214637. - Review
    5'-AMP-activated protein kinase (AMPK), a member of the serine/threonine (Ser/Thr) kinase group, is universally distributed in various cells and organs. It is a significa …
  • Neuroendocrine Aspects of Improving Sleep in Epilepsy
    DS Reddy et al. Epilepsy Res 147, 32-41. PMID 30212766. - Review
    Sleep plays an intricate role in epilepsy and can affect the frequency and occurrence of seizures. With nearly 35% of U.S. adults failing to obtain the recommended 7 h of …

Publication types

MeSH terms

Substances

Feedback